In many cases, this could be a successful therapeutic strategy, which would allow two families of ICIs to be included in the therapy without increasing the risk of suffering adverse renal effects (the incidence of kidney damage is not greater than after a single anti-CTLA-4). The gene discussed is CTLA4; the disease is Nephropathy.